Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer.
EBUS
Immunotherapy
Non-small cell lung cancer
Pembrolizumab
Pneumothorax
Journal
Respiratory medicine case reports
ISSN: 2213-0071
Titre abrégé: Respir Med Case Rep
Pays: England
ID NLM: 101604463
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
06
2020
revised:
08
10
2020
accepted:
11
10
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
5
11
2020
Statut:
epublish
Résumé
Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if programmed death-ligand 1 expression is ≥ 50%. All therapies for advanced stage disease have advantages and disadvantages, immunotherapy until now has presented mild adverse effects when compared to chemotherapy. However; it is known to induce inflammatory response to different tissues within the body. In our case acute pneumothorax was induced after immunotherapy administration.
Identifiants
pubmed: 33145157
doi: 10.1016/j.rmcr.2020.101258
pii: S2213-0071(20)30472-X
pmc: PMC7596337
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101258Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
All authors declare no conflict of interest.
Références
Ann Transl Med. 2015 Mar;3(3):41
pubmed: 25815302
Lung Cancer. 2020 Jan;139:179-184
pubmed: 31812129
Ann Oncol. 2013 Nov;24(11):2866-70
pubmed: 24026539
Respir Med Case Rep. 2017 Jul 14;22:101-105
pubmed: 28752057
Expert Rev Hematol. 2016;9(2):197-208
pubmed: 26629730
Ann Transl Med. 2015 Mar;3(3):43
pubmed: 25815304
Am Soc Clin Oncol Educ Book. 2015;:76-83
pubmed: 25993145
J Cancer. 2015 May 07;6(6):568-74
pubmed: 26000049
J Cancer. 2016 Jan 01;7(1):7-13
pubmed: 26722354
Respir Med Case Rep. 2017 Aug 29;22:197-202
pubmed: 28879076
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Respir Med Case Rep. 2018 Mar 02;23:182-187
pubmed: 29719813
Respir Med Case Rep. 2017 Oct 26;22:283-286
pubmed: 29124007
Cureus. 2019 Nov 26;11(11):e6233
pubmed: 31890432
Respirology. 2015 May;20(4):526-34
pubmed: 25682805
Radiol Clin North Am. 2012 Sep;50(5):863-76
pubmed: 22974775
J Med Econ. 2018 Dec;21(12):1191-1205
pubmed: 30188231
Respirology. 2016 Jul;21(5):821-33
pubmed: 27101251
N Engl J Med. 2017 Mar 9;376(10):997
pubmed: 28273022
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
Expert Rev Respir Med. 2020 Feb;14(2):125-136
pubmed: 31829747
Immunotherapy. 2018 Feb;10(2):93-105
pubmed: 29145737
Future Sci OA. 2019 Sep 25;5(9):FSO421
pubmed: 31608159
Cancer Treat Rev. 2019 Jul;77:20-28
pubmed: 31195212
J Thorac Dis. 2013 Sep;5 Suppl 4:S359-70
pubmed: 24102008
J Clin Oncol. 2012 Jul 20;30(21):2691-7
pubmed: 22614989
J Cancer. 2014 Mar 09;5(3):231-41
pubmed: 24665347
Zentralbl Chir. 2014 Sep;139 Suppl 1:S69-86; quiz S87
pubmed: 25264729
J Cancer. 2014 Feb 06;5(3):192-202
pubmed: 24563674